Edetek
Edetek is recorded as a service provider in 32 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 32 trials · Latest update first
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus
Sponsor Alumis Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis
Sponsor Shandong Boan Biotechnology Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study randomized 530 participants, exceeding the planned sample size of 524.
- The study was conducted at 39 sites in Bulgaria (4), the Czech Republic (2), Poland (19), Japan (11), and the United States (3).
- The Czech Republic applied a country-specific upper age limit of 75 years, whereas the overall eligibility range was 55 to 90 years.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Daraxonrasib (RMC-6236) in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Sponsor Oncoc4 Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
Sponsor Nurix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy versus Bulevirtide in Participants with Chronic HDV Infection (ECLIPSE 3)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Sponsor Immunome Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
Sponsor Olema Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Edetek?
The 2026-10-09 snapshot links Edetek to 32 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Electronic data capture, Stats Programing, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Edetek?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Hepatology, Solid Tumor Oncology, Endocrinology. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Edetek conducted?
The linked trials record locations in 19 countries, including Germany, France, Italy, Spain, Netherlands. These are trial locations, not confirmed office locations or countries where Edetek delivered services.
What can this page tell me about Edetek's trial experience?
Browse 32 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Edetek. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Edetek Inc.